[Liposteroid therapy for refractory epileptic spasms]

Area of Science:

• Neurology
• Pediatric Neurology

Background:

• Refractory epileptic spasms often require alternative treatments when standard therapies fail.
• Adrenocorticotropic hormone (ACTH) is a common treatment, but liposteroid is suggested as a safer alternative.

Observation:

• Intravenous liposteroid was administered to six patients with refractory epileptic spasms.
• Observed outcomes included transient spasm resolution, reappearance of spasms, and EEG improvement in one patient.
• Adverse effects such as behavioral changes, appetite loss, and increased tonic seizures were noted.

Findings:

• Liposteroid demonstrated a limited effect on refractory epileptic spasms, with only one patient experiencing complete resolution.
• Significant adverse effects were observed in multiple patients, necessitating discontinuation in one case.
• No serious adverse events like infection or brain shrinkage were reported.

Implications:

• Liposteroid may not be a consistently effective or safe alternative to ACTH for refractory epileptic spasms.
• The current liposteroid regimen requires modification to improve efficacy and reduce adverse effects.
• Further research is needed to optimize liposteroid therapy for pediatric epilepsy management.